Current state and perspectives of dendritic cell vaccination in cancer immunotherapy

A. Farkas, C. Conrad, G. Tonel, Z. Borbenyi, L. Kemény, A. Dobozy, F. O. Nestle

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Recent progress in the approach towards immunotherapy of cancer consists in molecular definition of tumor antigens, new tools for phenotypical and functional characterization of tumor-specific effector cells and clinical use of novel adjuvants for optimal stimulation of a cancer-specific immune response such as dendritic cells. In spite of these advances and immunological as well as clinical responses in selected patients, mechanisms involved in dendritic-cell-based cancer immunotherapy are still poorly understood. Therefore, a standardized study design and small pilot trials are needed to explore open scientific questions in future clinical trials. This review focuses on the different parameters of dendritic cell biology relevant to cancer immunotherapy and on innovative approaches to hopefully enhance the efficacy of dendritic cell vaccination.

Original languageEnglish
Pages (from-to)124-131
Number of pages8
JournalSkin Pharmacology and Physiology
Volume19
Issue number3
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Immunotherapy
Dendritic Cells
Vaccination
Neoplasms
Neoplasm Antigens
Cell Biology
Clinical Trials

Keywords

  • Cancer
  • Dendritic cell vaccination
  • Immunotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Physiology
  • Dermatology

Cite this

Current state and perspectives of dendritic cell vaccination in cancer immunotherapy. / Farkas, A.; Conrad, C.; Tonel, G.; Borbenyi, Z.; Kemény, L.; Dobozy, A.; Nestle, F. O.

In: Skin Pharmacology and Physiology, Vol. 19, No. 3, 06.2006, p. 124-131.

Research output: Contribution to journalArticle

Farkas, A. ; Conrad, C. ; Tonel, G. ; Borbenyi, Z. ; Kemény, L. ; Dobozy, A. ; Nestle, F. O. / Current state and perspectives of dendritic cell vaccination in cancer immunotherapy. In: Skin Pharmacology and Physiology. 2006 ; Vol. 19, No. 3. pp. 124-131.
@article{a0d0614902424c129006650bccaa84e6,
title = "Current state and perspectives of dendritic cell vaccination in cancer immunotherapy",
abstract = "Recent progress in the approach towards immunotherapy of cancer consists in molecular definition of tumor antigens, new tools for phenotypical and functional characterization of tumor-specific effector cells and clinical use of novel adjuvants for optimal stimulation of a cancer-specific immune response such as dendritic cells. In spite of these advances and immunological as well as clinical responses in selected patients, mechanisms involved in dendritic-cell-based cancer immunotherapy are still poorly understood. Therefore, a standardized study design and small pilot trials are needed to explore open scientific questions in future clinical trials. This review focuses on the different parameters of dendritic cell biology relevant to cancer immunotherapy and on innovative approaches to hopefully enhance the efficacy of dendritic cell vaccination.",
keywords = "Cancer, Dendritic cell vaccination, Immunotherapy",
author = "A. Farkas and C. Conrad and G. Tonel and Z. Borbenyi and L. Kem{\'e}ny and A. Dobozy and Nestle, {F. O.}",
year = "2006",
month = "6",
doi = "10.1159/000092592",
language = "English",
volume = "19",
pages = "124--131",
journal = "Skin Pharmacology and Physiology",
issn = "1660-5527",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Current state and perspectives of dendritic cell vaccination in cancer immunotherapy

AU - Farkas, A.

AU - Conrad, C.

AU - Tonel, G.

AU - Borbenyi, Z.

AU - Kemény, L.

AU - Dobozy, A.

AU - Nestle, F. O.

PY - 2006/6

Y1 - 2006/6

N2 - Recent progress in the approach towards immunotherapy of cancer consists in molecular definition of tumor antigens, new tools for phenotypical and functional characterization of tumor-specific effector cells and clinical use of novel adjuvants for optimal stimulation of a cancer-specific immune response such as dendritic cells. In spite of these advances and immunological as well as clinical responses in selected patients, mechanisms involved in dendritic-cell-based cancer immunotherapy are still poorly understood. Therefore, a standardized study design and small pilot trials are needed to explore open scientific questions in future clinical trials. This review focuses on the different parameters of dendritic cell biology relevant to cancer immunotherapy and on innovative approaches to hopefully enhance the efficacy of dendritic cell vaccination.

AB - Recent progress in the approach towards immunotherapy of cancer consists in molecular definition of tumor antigens, new tools for phenotypical and functional characterization of tumor-specific effector cells and clinical use of novel adjuvants for optimal stimulation of a cancer-specific immune response such as dendritic cells. In spite of these advances and immunological as well as clinical responses in selected patients, mechanisms involved in dendritic-cell-based cancer immunotherapy are still poorly understood. Therefore, a standardized study design and small pilot trials are needed to explore open scientific questions in future clinical trials. This review focuses on the different parameters of dendritic cell biology relevant to cancer immunotherapy and on innovative approaches to hopefully enhance the efficacy of dendritic cell vaccination.

KW - Cancer

KW - Dendritic cell vaccination

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=33745256759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745256759&partnerID=8YFLogxK

U2 - 10.1159/000092592

DO - 10.1159/000092592

M3 - Article

C2 - 16612139

AN - SCOPUS:33745256759

VL - 19

SP - 124

EP - 131

JO - Skin Pharmacology and Physiology

JF - Skin Pharmacology and Physiology

SN - 1660-5527

IS - 3

ER -